OBJECTIVES: To determine whether older adults with high plasma carboxymethyl-lysine (CML), an advanced glycation end product, are at higher risk of all-cause and cardiovascular disease (CVD) mortality. DESIGN: Prospective cohort study. SETTING: Population-based sample of adults aged 65 and older residing in Tuscany, Italy. PARTICIPANTS: One thousand thirteen adults participating in the Invecchiare in Chianti study. MEASUREMENTS: Anthropometric measures, plasma CML, fasting plasma total, high-density and low-density lipoprotein cholesterol, triglycerides, glucose, creatinine. Clinical measures: medical assessment, diabetes mellitus, hypertension, coronary heart disease, heart failure, stroke, cancer. Vital status measures: death certificates and causes of death according to the International Classification of Diseases. Survival methods were used to examine the relationship between plasma CML and all-cause and CVD mortality, adjusting for potential confounders. RESULTS: During 6 years of follow-up, 227 (22.4%) adults died, of whom 105 died with CVD. Adults with plasma CML in the highest tertile had greater all-cause (hazard ratio (HR)=1.84, 95% confidence interval) CI)=1.30-2.60, P<.001) and CVD (HR=2.11, 95% CI=1.27-3.49, P=.003) mortality than those in the lower two tertiles after adjusting for potential confounders. In adults without diabetes mellitus, those with plasma CML in the highest tertile had greater all-cause (HR=1.68, 95% CI=1.15-2.44, P=.006) and CVD (HR=1.74, 95% CI=1.00-3.01, P=.05) mortality than those in the lower two tertiles after adjusting for potential confounders. CONCLUSION: Older adults with high plasma CML are at higher risk of all-cause and CVD mortality.
OBJECTIVES: To determine whether older adults with high plasma carboxymethyl-lysine (CML), an advanced glycation end product, are at higher risk of all-cause and cardiovascular disease (CVD) mortality. DESIGN: Prospective cohort study. SETTING: Population-based sample of adults aged 65 and older residing in Tuscany, Italy. PARTICIPANTS: One thousand thirteen adults participating in the Invecchiare in Chianti study. MEASUREMENTS: Anthropometric measures, plasma CML, fasting plasma total, high-density and low-density lipoprotein cholesterol, triglycerides, glucose, creatinine. Clinical measures: medical assessment, diabetes mellitus, hypertension, coronary heart disease, heart failure, stroke, cancer. Vital status measures: death certificates and causes of death according to the International Classification of Diseases. Survival methods were used to examine the relationship between plasma CML and all-cause and CVD mortality, adjusting for potential confounders. RESULTS: During 6 years of follow-up, 227 (22.4%) adults died, of whom 105 died with CVD. Adults with plasma CML in the highest tertile had greater all-cause (hazard ratio (HR)=1.84, 95% confidence interval) CI)=1.30-2.60, P<.001) and CVD (HR=2.11, 95% CI=1.27-3.49, P=.003) mortality than those in the lower two tertiles after adjusting for potential confounders. In adults without diabetes mellitus, those with plasma CML in the highest tertile had greater all-cause (HR=1.68, 95% CI=1.15-2.44, P=.006) and CVD (HR=1.74, 95% CI=1.00-3.01, P=.05) mortality than those in the lower two tertiles after adjusting for potential confounders. CONCLUSION: Older adults with high plasma CML are at higher risk of all-cause and CVD mortality.
Authors: D A Kass; E P Shapiro; M Kawaguchi; A R Capriotti; A Scuteri; R C deGroof; E G Lakatta Journal: Circulation Date: 2001-09-25 Impact factor: 29.690
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt Journal: J Biol Chem Date: 1999-10-29 Impact factor: 5.157
Authors: B O Boehm; S Schilling; S Rosinger; G E Lang; G K Lang; R Kientsch-Engel; P Stahl Journal: Diabetologia Date: 2004-07-17 Impact factor: 10.122
Authors: Annelies W E Weverling-Rijnsburger; Iris J A M Jonkers; Eric van Exel; Jacobijn Gussekloo; Rudi G J Westendorp Journal: Arch Intern Med Date: 2003-07-14
Authors: Heather E Whitson; Alice M Arnold; Laura M Yee; Kenneth J Mukamal; Jorge R Kizer; Luc Djousse; Joachim H Ix; David Siscovick; Russell P Tracy; Stephen M Thielke; Calvin Hirsch; Anne B Newman; Susan Zieman Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-14 Impact factor: 6.053
Authors: Richard D Semba; Sarah K Gebauer; David J Baer; Kai Sun; Randi Turner; Harry A Silber; Sameera Talegawkar; Luigi Ferrucci; Janet A Novotny Journal: J Nutr Date: 2014-04-17 Impact factor: 4.798
Authors: Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2012-02-02 Impact factor: 4.799
Authors: R D Semba; A Ang; S Talegawkar; C Crasto; M Dalal; P Jardack; M G Traber; L Ferrucci; L Arab Journal: Eur J Clin Nutr Date: 2011-07-27 Impact factor: 4.016
Authors: Ashley R Wolf; Darryl A Wesener; Jiye Cheng; Alexandra N Houston-Ludlam; Zachary W Beller; Matthew C Hibberd; Richard J Giannone; Samantha L Peters; Robert L Hettich; Semen A Leyn; Dmitry A Rodionov; Andrei L Osterman; Jeffrey I Gordon Journal: Cell Host Microbe Date: 2019-10-01 Impact factor: 21.023